Grifols Safety Trials

Grifols today said it plans to initiate a safety trial later this year of a new inhaled formulation for treating emphysema due to alpha1-proteinase inhibitor deficiency.

The Barcelona, Spain-based company said it would initiate a safety trial of a novel, inhaled formulation of alpha1-proteinase inhibitor (Human), following orphan drug designation for cystic fibrosis.

“Grifols is committed to developing new therapies that address the debilitating symptoms of chronic lung disease,” said Kim Hanna, vice president of clinical research development at Grifols. “The orphan drug designation represents another milestone in the growth of our alpha1 program, and we’re excited to pursue clinical trials with an aerosol formulation of this important therapy.“